In this episode of the Oncology Brothers podcast, we welcomed Dr. Petros Grivas, medical oncologist from the Fred Hutch Cancer Center, who walked through practice-changing and practice-reinforcing data across bladder cancer, kidney cancer, and prostate cancer.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

X/Twitter: https://twitter.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Key topics discussed included:

CREST & POTOMAC: IO-BCG combination data in high-risk BCG-naive NMIBC, both demonstrating a hazard ratio of 0.68 for DFS / EFS.
EV-304/KEYNOTE-B15: established EV-Pembrolizumab as the new perioperative standard of care for resectable muscle-invasive bladder cancer regardless of cisplatin eligibility, with a pathological complete response rate of 56% and overall survival hazard ratio of 0.65.
LITESPARK-022 & LITESPARK-011: data exploring Belzutifan combinations in adjuvant and refractory RCC settings, while managing key toxicities of anemia and hypoxia.
CAPITELLO-281: evaluating capivasertib in PTEN-deficient metastatic hormone-sensitive prostate cancer, where patient related outcomes were reported.

Join us for this comprehensive discussion covering the latest GU oncology advances that will directly impact your clinical practice. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology!

#GUASCO2026, #BladderCancer, #RenalCellCarcinoma, #ProstateCancer, #OncBrothers

GU ASCO 2026 Highlights – CREST, POTOMAC, EV-304/KEYNOTE-B15, LITESPARK-011/022, CAPITELLO-281